Brian Robbins, PhD.

Brian Robbins, PhD.

RobbinsResearch Associate Professor
Manager, Antiviral Pharmacology Laboratory
Department of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
986045 Nebraska Medical Center
Omaha, NE   68198-6045
Phone: 402-559-1939
Fax:  402-559-5060
Email:  blrobbins@unmc.edu

Research Activities/Interests
In our laboratory we investigate the metabolism, disposition and pharmacokinetics of currently used and new anti-HIV compounds.  This includes a variety of compounds that inhibit most of the known inhibition sites of the HIV life cycle.  These include following classes, protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), non nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitors.  Using LC-MS/MS technology we have developed unique assays to quantitate low concentrations of the active forms of the NRTI found in human peripheral blood mononuclear cells and will continue this line of research with some of the other drugs in related tissues of interest such as gut associated lymphoid tissue.  We are also planning to investigate drug levels in dried blood spots to allow easier shipment from remote locations overseas.

Recent Publications:

  1. Chadwick EG, Yogev R, Alvero CG, Hughes MD, Hazra R, Pinto JA, Robbins BL, Heckman BE, Palumbo PE, Capparelli EV, IMPAACT P1030 Team.  Long Outcomes for HIV-Infected Infants Less than 6 Months of Age at Initiation of Lopinavir/Ritonavir Combination Antiretroviral Therapy (2011) ADIS March 13; 25(5):643-9.
  2. Van Schooneveld T, Swindells S, Nelson SR, Robbins BL, Moore R, Fletcher CV. Clinical Evaluation of a Dried Blood Spot Assay for Atazanavir (2010) Antimicrob. Agents Chemother. Oct; 54(10): 4124-8.
  3. Delahunty T, Bushman L, Robbins B, Fletcher CV. The Simultaneous Assay of Tenofovir and Emtricitabine in Plasma using LC/MS/MS and Isotopically Labeled Internal Standards (2009) J Chromatogr B Analyt Technol Biomed Life Sci Jul 1; 877(20-21): 1907-14. 
  4. Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Plaumbo P, Robbins B, Hazra R, Serchuck L, Heckman BE, Purdue L, Browning R, Luzuriaga K, Rodman J, Capparelli E IMPAACT P1030 Team.  Early Initiation of Lopinavir/Ritonavir in Infants Less than 6 Weeks of Age. Pharmacokinetics nad 24-week Safety and Efficacy (2009) Pediatr. Infect Dis J. Mar 28(3):215-9.
  5. Cross SJ, Rodman JH, Lindsey J, Robbins BL, Rose C, Yuen GK and D'Angelo L. Abacavir Pharmacokinetics in HIV-1 Infected Children and Adolescents (2009)  J. Acquir. Immune. Defic. Syndr. May 1; 51(1):54-9.
  6. Robbins BL, Havens PL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrel C, Alvero C, Heckman B, Pelton SI, Aldrovandi G, Borokowsky W, and Rodman J for the P1038 Team. Pharmacokinetics of High-Dose Lopinavir/Ritonavir with and without Saquinavir or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors (2008) Antimicrob Agents Chemother. Sep; 52(9):3276-83.
  7. Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins BL, Rodman J, Chen J, Palumbo P, Serchuck L, Hughes M for the P1030 team. Pharmacokinetics, Safety and Efficacy of Lopinavir/ritonavir in Infants Less than Six Months of Age: 24 Week Results (2008) AIDS Jan11; 22(2):249-55.